[Skip to Content]
[Skip to Content Landing]
Article
April 1989

Misoprostol Heals Gastroduodenal Injury in Patients With Rheumatoid Arthritis Receiving Aspirin

Author Affiliations

From the Arthritis Center Ltd, Phoenix (Dr Roth); Tulane University School of Medicine, New Orleans (Dr Agrawal); Veterans Administration Medical Center, Minneapolis (Dr Mahowald); Winona Memorial Hospital, Indianapolis (Dr Montoya); Division of Rheumatology/Allergy, University of California, Davis (Dr Robbins); and the G. D. Searle and Company, Skokie, Ill (Drs Miller, Nutting, Crager, Swabb, and Messrs Woods and Nissen).

Arch Intern Med. 1989;149(4):775-779. doi:10.1001/archinte.1989.00390040017004
Abstract

• High-dose aspirin therapy for rheumatoid arthritis is frequently associated with severe gastrointestinal injury. To explore the possibility of reversing such damage, we conducted a double-blind, multicenter study with misoprostol, a prostaglandin E1 analog, which has demonstrated mucosal protective, gastric antisecretory, and ulcer healing properties. We also studied possible interference of misoprostol with continuing aspirin treatment in the management of patients with rheumatoid arthritis. Patients with confirmed rheumatoid arthritis and endoscopically documented gastroduodenal lesions were randomly assigned to receive 200 μg of misoprostol four times a day (123 patients) or placebo (116 patients). Each concurrently received 650 to 1300 mg of aspirin four times a day. After eight weeks of treatment, misoprostol was statistically superior to placebo in healing gastric mucosal injury (70% vs 25%) and duodenal mucosal injury (86% vs 53%). Patients with gastric or duodenal ulcers on admission had superior ulcer healing rates with misoprostol (67% vs 26%). There was no evidence of interference with the antirheumatic properties of aspirin. Mild to moderate adverse experiences were equally noted in misoprostol and placebo groups. Misoprostol, coadministered with aspirin, is well tolerated and highly effective in healing aspirin-associated gastroduodenal lesions in patients with rheumatoid arthritis without altering the therapeutic benefits of aspirin.

(Arch Intern Med 1989;149:775-779)

References
1.
Roth SH:  Salicylates , in Roth SH, Calabro JJ (eds): Rheumatic Therapeutics . New York, McGraw-Hill International Book Co, 1985, pp 309-323.
2.
Lanza FL, Royer GL, Nelson RS, et al:  Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa . N Engl J Med 1980;303:136-138.Article
3.
Lanza FL, Royer GL, Nelson RS, et al:  A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa . Am J Gastroenterol 1981;75:17-21.
4.
Morris AD, Holt SD, Silvoso GR, et al:  Effect of anti-inflammatory drug administration in patients with rheumatoid arthritis: An endoscopic assessment . Scand J Gastroenterol 1981;16( (suppl 67) ):131-135.
5.
Ivey KJ:  Aspirin gastrointestinal toxicity: A review . Adv Ther 1984;1: 190-206.
6.
Silvoso GR, Ivey KJ, Butt JH, et al:  Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy . Ann Intern Med 1979;91:517-520.Article
7.
Collier DSJ, Pain JA:  Non-steroidal anti-inflammatory drugs and peptic ulcer perforation . Gut 1985;26:359-363.Article
8.
Peoples JB:  Peptic ulcer disease and the nonsteroidal anti-inflammatory drugs . Am Surg 1985;51:358-362.
9.
Jacyna MR, Shepherd AN:  Perforated ulcer in the elderly . Lancet 1985;2:1309.Article
10.
Clinch D, Banerjee AK, Ostick G, et al:  Non-steroidal anti-inflammatory drugs and gastrointestinal adverse effects . J R Coll Physicians Lond 1983;17:228-230.
11.
Walt R, Katschinski B, Logan R, et al:  Rising frequency of ulcer perforation in elderly people in the United Kingdom . Lancet 1986;1:489-492.Article
12.
Davenport HW:  Gastric mucosal injury by fatty and acetylsalicylic acids . Gastroenterology 1964;46:245-253.
13.
Lanza FL, Rack MF, Wagner GS, et al:  Reduction in gastric mucosal hemorrhage and ulceration with chronic high-level dosing of enteric-coated aspirin granules two and four times a day . Dig Dis Sci 1985;30:509-512.Article
14.
Petroski D:  A comparison of enteric-coated aspirin granules with plain and buffered aspirin: A report of two studies . Am J Gastroenterol 1986;81:26-28.
15.
Dajani EZ:  Perspective on the gastric antisecretory effects of misoprostol in man . Prostaglandins 1987;33( (suppl) ):68-77.Article
16.
Tsai BS, Kessler LK, Schoenhard G, et al:  Demonstration of specific E-type prostaglandin receptors using enriched preparations of canine parietal cells and [3H]misoprostol free acid . Am J Med 1987;83( (suppl 1A) ): 9-14.Article
17.
Dajani EZ:  Overview of the mucosal protective effects of misoprostol in man . Prostaglandins 1987;33( (suppl) ):117-129.Article
18.
Isenberg JI, Hogan DL, Koss MA, et al:  Human duodenal mucosal bicarbonate secretion: Evidence for basal secretion and stimulation by hydrochloric acid and a synthetic prostaglandin E1 analog . Gastroenterology 1986;91:370-378.
19.
Wilson DE, Quadros E, Rajapaksa T, et al:  Effects of misoprostol on gastric acid and mucus secretion in man . Dig Dis Sci 1986;31( (suppl) ):126s-129s.Article
20.
Sato N, Kawano S, Fukada M:  The effect of misoprostol on gastric mucosal hemodynamics in man: A possible mechanism of cytoprotection, abstracted . Gastroenterology 1986;90:1616.
21.
Lanza FL, Aspinall RL, Swabb EA, et al:  Double blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum . Gastroenterology 1988;95:289-294.
22.
Aadland E, Fausa O, Vatn M, et al:  Protection by misoprostol against naproxen-induced gastric mucosal damage . Am J Med 1987;83( (suppl 1A) ): 37-40.Article
23.
Hunt JN, Smith JL, Jiang CL, et al:  Effect of synthetic prostaglandin E1 analog on aspirin-induced gastric bleeding and secretion . Dig Dis Sci 1983;28:897-902.Article
24.
Cohen MM, Clark L, Armstrong L, et al:  Reduction of aspirin-induced fecal blood loss with low dose misoprostol tablets in man . Dig Dis Sci 1985;30:605-611.Article
25.
Silverstein FE:  Gastric protection by misoprostol against 1300 mg of aspirin: An endoscopic study . Dig Dis Sci 1986;31( (suppl) ):137s-141s.Article
26.
Agrawal NM, Saffouri B, Kruss DM, et al:  Healing of benign gastric ulcer: A placebo controlled comparison of two dosage regimens of misoprostol, a synthetic analog of prostaglandin E1 . Dig Dis Sci 1985; 30( (suppl) ):164s-170s.Article
27.
Brand DL, Roufail WM, Thompson ABR, et al:  Misoprostol, a synthetic PGE, analog, in the treatment of duodenal ulcers: A multicenter double-blind study . Dig Dis Sci 1985;30( (suppl) ):147s-158s.Article
28.
Ropes MW, Bennett GA, Cobb S, et al:  1958 revision of diagnostic criteria for rheumatoid arthritis . Bull Rheum Dis 1958;9:175-176.
29.
Steinbrocker O, Traeger CH, Batterman RC:  Therapeutic criteria in rheumatoid arthritis . JAMA 1949;140:659-662.Article
30.
Duggan JM:  The pathogenesis of the aspirin-related gastric lesion . J R Coll Physicians Lond 1981;15:117-118.
31.
Dajani EZ:  Is peptic ulcer a prostaglandin deficiency disease? Hum Pathol 1986;17:106-107.Article
32.
Rainsford KD:  The biochemical pathology of aspirin induced gastric damage . Agents Actions 1975;5:326-344.Article
33.
Cooke AR:  The role of acid in the pathogenesis of aspirin induced gastrointestinal erosions and hemorrhage . Am J Dig Dis 1973;18:225-237.Article
34.
Bland J:  Absorption of enteric coated aspirin . JAMA 1983;249:59.Article
35.
Flower RJ, Moncada S, Vane JR:  Analgesic-antipyretics and anti-inflammatory agents: Drugs employed in the treatment of gout , in Goodman AG, Goodman LS, Rall TW, et al (eds): The Pharmacological Basis of Therapeutics , ed 7. New York, Macmillan Publishing Co Inc, 1985, pp 674-715.
36.
Bugat R, Thompson MR, Aures D, et al:  Gastric mucosal lesions produced by intravenous infusion of aspirin in cats . Gastroenterology 1976; 71:754-759.
37.
Roth SH, Bennett RE:  Non-steroidal anti-inflammatory drug gastropathy: Recognition and response . Arch Intern Med 1987;147:2093-2100.Article
38.
O'Laughlin JC, Silvoso GK, Ivey KJ:  Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin: A double blind study with cimetidine and follow up . Dig Dis Sci 1982;27:976-980.Article
39.
Davies J, Collins AJ, Dixon SA:  The influence of cimetidine on peptic ulcer in patients with arthritis taking anti-inflammatory drugs . Br J Rheumatol 1986;25:54-58.Article
40.
Croker JR, Cotton JB, Boyle AC, et al:  Cimetidine for peptic ulcer in patients with arthritis . Ann Rheum Dis 1980;39:275-278.Article
41.
Roth SH, Bennett RE, Mitchell CS, et al:  Cimetidine therapy in non-steroidal anti-inflammatory drug gastropathy: Double blind, long-term evaluation . Arch Intern Med 1987;147:1798-1801.Article
42.
Loiudice TA, Saleem T, Lang JA:  Cimetidine in the treatment of gastric ulcer induced by steroidal and non-steroidal anti-inflammatory agents . Am J Gastroenterol 1981;75:104-110.
×